Epigenetic drug target deconvolution by mass spectrometry–based technologies

ABSTRACT The identification of the full target spectrum of active molecules, known as target deconvolution, has become an indispensable step during the drug discovery process. It is now

achievable thanks to mass spectrometry–based technologies. Here we discuss these approaches in the context of epigenetic drug discovery. Access through your institution Buy or subscribe This

is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our

best-value online-access subscription $32.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue

Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL

ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS DECRYPTING THE MOLECULAR BASIS OF

CELLULAR DRUG PHENOTYPES BY DOSE-RESOLVED EXPRESSION PROTEOMICS Article Open access 07 May 2024 TARGET DECONVOLUTION OF HDAC PHARMACOPOEIA REVEALS MBLAC2 AS COMMON OFF-TARGET Article 28

April 2022 THE EMERGING ROLE OF MASS SPECTROMETRY-BASED PROTEOMICS IN DRUG DISCOVERY Article 29 March 2022 REFERENCES * Portela, A. & Esteller, M. Epigenetic modifications and human

disease. _Nat. Biotechnol._ 28, 1057–1068 (2010). Article  CAS  PubMed  Google Scholar  * Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K. & Schapira, M. Epigenetic protein families:

a new frontier for drug discovery. _Nat. Rev. Drug Discov._ 11, 384–400 (2012). Article  CAS  PubMed  Google Scholar  * Prachayasittikul, V. et al. Exploring the epigenetic drug discovery

landscape. _Expert Opin. Drug Discov._ 12, 345–362 (2017). Article  CAS  PubMed  Google Scholar  * Atadja, P. & Perez, L. in _Successful Drug Discovery_, Vol. 2, 59–88 (Wiley Online

Library, 2016). * Dittmann, A. et al. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains. _ACS Chem. Biol._ 9, 495–502 (2014). Article  CAS  PubMed  Google

Scholar  * Bantscheff, M., Scholten, A. & Heck, A. J. Revealing promiscuous drug-target interactions by chemical proteomics. _Drug Discov. Today_ 14, 1021–1029 (2009). Article  CAS 

PubMed  Google Scholar  * Rix, U. & Superti-Furga, G. Target profiling of small molecules by chemical proteomics. _Nat. Chem. Biol._ 5, 616–624 (2009). Article  CAS  PubMed  Google

Scholar  * Sharma, K. et al. Proteomics strategy for quantitative protein interaction profiling in cell extracts. _Nat. Methods_ 6, 741–744 (2009). Article  CAS  PubMed  Google Scholar  *

Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. _Nat. Biotechnol._ 25, 1035–1044 (2007). Article  CAS  PubMed  Google

Scholar  * Taunton, J., Hassig, C. A. & Schreiber, S. L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. _Science_ 272, 408–411 (1996). Article  CAS

  PubMed  Google Scholar  * Weigt, D., Hopf, C. & Médard, G. Studying epigenetic complexes and their inhibitors with the proteomics toolbox. _Clin. Epigenetics_ 8, 76 (2016). Article 

PubMed  PubMed Central  Google Scholar  * Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. _Nat. Biotechnol._ 29, 255–265

(2011). Article  CAS  PubMed  Google Scholar  * Niphakis, M. J. & Cravatt, B. F. Enzyme inhibitor discovery by activity-based protein profiling. _Annu. Rev. Biochem._ 83, 341–377 (2014).

Article  CAS  PubMed  Google Scholar  * Salisbury, C. M. & Cravatt, B. F. Activity-based probes for proteomic profiling of histone deacetylase complexes. _Proc. Natl Acad. Sci. USA_

104, 1171–1176 (2007). Article  CAS  PubMed  PubMed Central  Google Scholar  * Chung, C. W. et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains.

_J. Med. Chem._ 54, 3827–3838 (2011). Article  CAS  PubMed  Google Scholar  * Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion

leukaemia. _Nature_ 478, 529–533 (2011). Article  CAS  PubMed  PubMed Central  Google Scholar  * Savitski, M. M. et al. Tracking cancer drugs in living cells by thermal profiling of the

proteome. _Science_ 346, 1255784 (2014). Article  PubMed  Google Scholar  * Franken, H. et al. Thermal proteome profiling for unbiased identification of direct and indirect drug targets

using multiplexed quantitative mass spectrometry. _Nat. Protoc._ 10, 1567–1593 (2015). Article  CAS  PubMed  Google Scholar  * Becher, I. et al. Thermal profiling reveals phenylalanine

hydroxylase as an off-target of panobinostat. _Nat. Chem. Biol._ 12, 908–910 (2016). Article  CAS  PubMed  Google Scholar  * Olsen, J. V. & Mann, M. Status of large-scale analysis of

post-translational modifications by mass spectrometry. _Mol. Cell. Proteomics_ 12, 3444–3452 (2013). CAS  PubMed  PubMed Central  Google Scholar  * Greiner, D., Bonaldi, T., Eskeland, R.,

Roemer, E. & Imhof, A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. _Nat. Chem. Biol._ 1, 143–145 (2005). Article  CAS  PubMed  Google Scholar  *

Garcia, B. A., Busby, S. A., Shabanowitz, J., Hunt, D. F. & Mishra, N. Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition.

_J. Proteome Res._ 4, 2032–2042 (2005). Article  CAS  PubMed  Google Scholar  * Lee, A. Y. et al. Quantitative analysis of histone deacetylase-1 selective histone modifications by

differential mass spectrometry. _J. Proteome Res._ 7, 5177–5186 (2008). Article  CAS  PubMed  Google Scholar  * Xu, K. et al. EZH2 oncogenic activity in castration-resistant prostate cancer

cells is Polycomb-independent. _Science_ 338, 1465–1469 (2012). Article  CAS  PubMed  PubMed Central  Google Scholar  * Schölz, C. et al. Acetylation site specificities of lysine deacetylase

inhibitors in human cells. _Nat. Biotechnol._ 33, 415–423 (2015). Article  PubMed  Google Scholar  * Musiani, D. et al. Proteomics profiling of arginine methylation defines PRMT5 substrate

specificity. _Sci. Signal._ 12, eaat8388 (2019). Article  CAS  PubMed  Google Scholar  * Noberini, R., Sigismondo, G. & Bonaldi, T. The contribution of mass spectrometry-based proteomics

to understanding epigenetics. _Epigenomics_ 8, 429–445 (2016). Article  CAS  PubMed  Google Scholar  * Schirle, M., Bantscheff, M. & Kuster, B. Mass spectrometry-based proteomics in

preclinical drug discovery. _Chem. Biol._ 19, 72–84 (2012). Article  CAS  PubMed  Google Scholar  * Krönke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple

myeloma cells. _Science_ 343, 301–305 (2014). Article  PubMed  Google Scholar  * Schopper, S. et al. Measuring protein structural changes on a proteome-wide scale using limited

proteolysis-coupled mass spectrometry. _Nat. Protoc._ 12, 2391–2410 (2017). Article  CAS  PubMed  Google Scholar  * Anders, L. et al. Genome-wide localization of small molecules. _Nat.

Biotechnol._ 32, 92–96 (2014). Article  CAS  PubMed  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Experimental Oncology, IEO, European

Institute of Oncology IRCCS, Milano, Italy Roberta Noberini & Tiziana Bonaldi Authors * Roberta Noberini View author publications You can also search for this author inPubMed Google

Scholar * Tiziana Bonaldi View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Tiziana Bonaldi. ETHICS DECLARATIONS

COMPETING INTERESTS The authors declare no competing interests. ADDITIONAL INFORMATION PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published

maps and institutional affiliations. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Noberini, R., Bonaldi, T. Epigenetic drug target deconvolution by

mass spectrometry–based technologies. _Nat Struct Mol Biol_ 26, 854–857 (2019). https://doi.org/10.1038/s41594-019-0279-x Download citation * Received: 19 June 2019 * Accepted: 15 July 2019

* Published: 03 October 2019 * Issue Date: October 2019 * DOI: https://doi.org/10.1038/s41594-019-0279-x SHARE THIS ARTICLE Anyone you share the following link with will be able to read this

content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative